BTIG Research Forecasts Strong Price Appreciation for Carlsmed (NASDAQ:CARL) Stock

Carlsmed (NASDAQ:CARL) had its price target boosted by investment analysts at BTIG Research from $21.00 to $24.00 in a report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would indicate a potential upside of 75.70% from the stock’s previous close.

Separately, Weiss Ratings started coverage on shares of Carlsmed in a report on Thursday, October 16th. They issued a “sell (e)” rating on the stock. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Carlsmed currently has a consensus rating of “Hold” and an average target price of $22.00.

Carlsmed Stock Performance

NASDAQ:CARL opened at $13.66 on Friday. Carlsmed has a one year low of $11.76 and a one year high of $16.20. The stock has a 50-day simple moving average of $13.59.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.05. Carlsmed has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CARL. Vanguard Group Inc. bought a new stake in shares of Carlsmed during the 3rd quarter valued at about $3,042,000. Teacher Retirement System of Texas acquired a new position in Carlsmed in the third quarter valued at approximately $2,343,000. TD Waterhouse Canada Inc. bought a new position in shares of Carlsmed during the third quarter valued at approximately $2,026,000. Kornitzer Capital Management Inc. KS acquired a new stake in shares of Carlsmed during the 3rd quarter worth approximately $736,000. Finally, Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of Carlsmed in the 3rd quarter worth approximately $335,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).